Oct. 22 at 1:10 PM
$ALZN In doing a followup to my previous post about lithium market, I did find where lithium is less than
$20 a month, so I'm adjusting annual revenue back to
$750M. I then looked at top 50 pharmas and their revenue to marketcap ratio. It ranges from 2 to 10. So let's be conservative a go with 2 x
$750 =MC of
$1.5B. Let's say Alzn gets a bump in price from current trial and with an annoucement of starting P2B BP trial at Harvard. and they do offering of 2M more shares. Then a future projected MC of
$1,5B divided 6M shares =
$250 a share. Here's another interesting tidbit about lithium. There is a lot of talk in the medical community saying lithium should be prescribed more than it is, because it is the "Gold Standard". It just has a toxicity
issue. "IF" Alzn can remedy that and they price Al001 competitive with generic, then insurance (the gate keeper) would love to switch patients from a more expensive to a cheaper, better drug and that MC goes up even more(BP-US-7M) (WW 46M)
